Request Trial
Shohta Ueno (L) Edger Brinkman (R)
4 November 2025NewsUnified Patent CourtTom Phillips

Regeneron and CureVac: UPC ‘cannot be ignored’

Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Unified Patent Court
WATCH: Navigating parallel EPO and UPC revocation actions: strategies, opportunities, and risks
23 May 2026   Managing parallel revocation actions requires a meticulous approach to forum choice and sequencing. This presentation unpacks the lessons learned from the first year of simultaneous EPO and UPC proceedings, offering tactics to leverage opportunities and minimise cross-border risks.
Unified Patent Court
WATCH: Facilitating access to the UPC—economics and navigating the UPC-US patent nexus
15 May 2026   Understanding the economic mechanisms and cross-border interactions of the UPC is crucial for modern patent litigation. This session untangles the complexities of evidence gathering and cost security, highlighting the critical interplay between European proceedings and US patent strategies.
Unified Patent Court
WATCH: Latest developments from the UPC
14 May 2026   Are life sciences cases gaining momentum in the new Unified Patent Court? This session provides a critical update on the UPC's evolving jurisprudence, looking at emerging legal tests and the specific challenges of preliminary injunctions for life sciences products.


Editor's picks

Pfizer’s US Paxlovid patent fight turns on a single error
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026

Editor's picks

Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026

More features

Ashurst Perkins Coie opens its doors following landmark merger
Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Novo secures website blocking to tackle fake weight-loss drugs
GLP-1 patents and Africa: The COVID-19 lessons we still have not learned
Cooley Asia transactions duo make rival firm move
Insilico lands potential $2.5bn AI biotech partnership